Natural Alternatives International (NAII) Competitors $3.44 +0.01 (+0.29%) As of 07/10/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAII vs. PLRX, ZURA, EPIX, QNCX, SRZN, INCR, IMMX, ABOS, IMUX, and GNTAShould you be buying Natural Alternatives International stock or one of its competitors? The main competitors of Natural Alternatives International include Pliant Therapeutics (PLRX), Zura Bio (ZURA), ESSA Pharma (EPIX), Quince Therapeutics (QNCX), Surrozen (SRZN), InterCure (INCR), Immix Biopharma (IMMX), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry. Natural Alternatives International vs. Its Competitors Pliant Therapeutics Zura Bio ESSA Pharma Quince Therapeutics Surrozen InterCure Immix Biopharma Acumen Pharmaceuticals Immunic Genenta Science Natural Alternatives International (NASDAQ:NAII) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Does the media refer more to NAII or PLRX? In the previous week, Pliant Therapeutics had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for Pliant Therapeutics and 1 mentions for Natural Alternatives International. Pliant Therapeutics' average media sentiment score of 1.73 beat Natural Alternatives International's score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Natural Alternatives International Neutral Pliant Therapeutics Very Positive Do institutionals & insiders hold more shares of NAII or PLRX? 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 20.9% of Natural Alternatives International shares are held by company insiders. Comparatively, 8.0% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is NAII or PLRX more profitable? Pliant Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.56%. Natural Alternatives International's return on equity of -10.34% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.56% -10.34% -5.19% Pliant Therapeutics N/A -67.56%-52.54% Which has more risk & volatility, NAII or PLRX? Natural Alternatives International has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Do analysts prefer NAII or PLRX? Pliant Therapeutics has a consensus price target of $13.31, suggesting a potential upside of 850.89%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings & valuation, NAII or PLRX? Natural Alternatives International has higher revenue and earnings than Pliant Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$125.48M0.17-$7.22M-$1.39-2.52Pliant Therapeutics$1.58M54.40-$210.30M-$3.61-0.39 SummaryPliant Therapeutics beats Natural Alternatives International on 9 of the 15 factors compared between the two stocks. Get Natural Alternatives International News Delivered to You Automatically Sign up to receive the latest news and ratings for NAII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAII vs. The Competition Export to ExcelMetricNatural Alternatives InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.63M$2.43B$5.55B$9.02BDividend YieldN/A1.79%5.25%4.04%P/E Ratio-2.529.3827.1820.14Price / Sales0.17483.65379.4880.15Price / CashN/A164.1737.5058.41Price / Book0.264.698.075.60Net Income-$7.22M$31.26M$3.16B$248.43M7 Day Performance9.03%6.81%4.71%5.47%1 Month Performance2.34%5.93%4.52%7.87%1 Year Performance-38.60%-1.03%30.82%18.75% Natural Alternatives International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAIINatural Alternatives International0.4205 of 5 stars$3.50+2.0%N/A-38.8%$21.63M$125.48M-2.52290Gap DownPLRXPliant Therapeutics4.4056 of 5 stars$1.18-6.3%$13.31+1,028.2%-87.4%$77.35M$1.58M-0.3390News CoveragePositive NewsZURAZura Bio2.4572 of 5 stars$1.10-2.7%$14.33+1,203.0%-61.9%$77.26MN/A-1.573News CoveragePositive NewsGap UpEPIXESSA Pharma1.3625 of 5 stars$1.70-2.3%$2.00+17.6%-66.6%$77.24MN/A-2.7050Positive NewsQNCXQuince Therapeutics3.1776 of 5 stars$1.63+1.2%$8.00+390.8%+147.2%$73.21MN/A-1.1760SRZNSurrozen2.275 of 5 stars$8.35-0.1%$38.50+361.1%-11.4%$71.58M$10.65M-0.3380INCRInterCure0.497 of 5 stars$1.50-3.8%N/A-30.2%$71.09M$238.85M0.00350High Trading VolumeIMMXImmix Biopharma3.6563 of 5 stars$2.62+2.7%$7.00+167.2%+32.8%$71.09MN/A-3.749ABOSAcumen Pharmaceuticals1.7954 of 5 stars$1.16flat$6.33+446.0%-43.2%$70.26MN/A-0.6020News CoveragePositive NewsIMUXImmunic2.6728 of 5 stars$0.77+5.2%$11.60+1,416.3%-34.4%$69.68MN/A-0.6270GNTAGenenta Science1.9271 of 5 stars$3.98+4.7%$25.00+528.1%+33.1%$69.50MN/A0.007News CoverageGap Up Related Companies and Tools Related Companies Pliant Therapeutics Competitors Zura Bio Competitors ESSA Pharma Competitors Quince Therapeutics Competitors Surrozen Competitors InterCure Competitors Immix Biopharma Competitors Acumen Pharmaceuticals Competitors Immunic Competitors Genenta Science Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAII) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natural Alternatives International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natural Alternatives International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
